

For Immediate Release

Contacts:

Joel Ranck

202-832-0478

jranck@lincolnparkcom.com

Eric Langer, BioPlan Associates, Inc.

(301) 921-9074

elanger@bioplanassociates.com

47 Recently Approved Biopharmaceutical Products Included in Biotherapeutics Reference Compendium

September 28, 2005 (Washington, DC) – The 4th Edition, *Biopharmaceutical Products in the US and European Markets* was expanded to include comprehensive product monographs on 482 marketed biotherapeutics in the US and Europe, including 47 recently approved products.

The 4th edition includes unique information on most marketed biopharmaceuticals, from Anthrax Vaccines to VEGF aptamer. In addition, many biodefense and biogeneric products are included.

According to JS Williamson, PhD Univ. University of Mississippi, Society of Industrial Microbiology, the book is a “one of kind publication...a must for any biotechnology library, including those in academia...I find it to be filled with some of the most interesting and insightful information on biopharmaceuticals... I have found myself thumbing through it as if it were an almanac...the most useful and cost-effective resource with the information you need to understand biopharmaceutical products and the industry.”

The reference book includes insightful information on biopharmaceuticals, and is a useful and cost-effective resource with the information needed to understand biopharmaceutical products and the industry. The study comprehensively covers marketed biopharmaceutical drugs. It provides in-depth information and intelligent value-added indexing. This indexing is an essential resource for those seeking technology or competitive intelligence on biopharmaceutical companies. The entries cover basic elements such as names and action, but unique to this work, the entries also include organizations involved in the development and production, manufacturing process, location of production, manufacturers, history of patent transfers, controversial aspects, and market data. The exacting detail and thoroughness, and the extensive indexing makes it valuable for general, technical, and competitive information.

The report includes 482 comprehensive, individual product monographs, in 1234 pages, covering all US biotechnology products on the market, and most European products. Provides detailed descriptions and indexing, legal, manufacturing, competitive, marketing, technological and regulatory intelligence; It includes unique and hard-to-find

primary information. In addition, it provides product information and manufacturing technologies; competitive intelligence regarding what has happened commercially; technology transfer aspects, including patents, disputes and other information; it includes legal aspects of the product; and scientific and technical material such as biological activity therapeutic basis, expression and host systems. In addition, licensing and partnership information are provided, based on countries; regulatory aspects including approved indications, approval dates, precedents set, current status; Market size, share, and trends; business development partnering and sales information are also provided.

Coverage includes: Recombinant & other proteins; monoclonal antibodies; vaccines, adjuvants; enzymes & toxins; blood products, human & animal-derived; radioimmune conjugates; cultured cells; tissue products; antisense drugs, defense vaccines, and biogenerics.

The reference work is published by BioPlan Associates, Inc., which has provided publication services, market assessment, and market research to biopharmaceutical, biotechnology, and healthcare companies since 1989 (www.bioplanassociates.com). 15200 Shady Grove Road, Suite 202, Rockville, MD 20850 Tel: 301-921-9074

###